drugset
drugset / Trial / NCT07193563

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

NCT07193563 ↗

Phase 2 Completed 47 enrolled Engrail Therapeutics INC
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).

Timeline

Start
2025-09-05
Primary completion
2026-03-19
Completion
2026-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ENX-102 Unknown 2 mg Oral

Indications

social phobia